Condition: mCRPC (Metastatic Castration-resistant Prostate Cancer) · Genital Diseases, Male · Urogenital Diseases, Male · Sponsor: Celcuity Inc
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.
This description comes directly from the study's public registry record.
Genelle Brower, RN · 844-310-3900 · gbrower@celcuity.com
Always discuss trial participation with your own doctor first.
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Not Yet Recruiting |
| Institut Paoli-Calmettes | Marseille, France | Not Yet Recruiting |
| Centre Antoine Lacassagne | Nice, France | Not Yet Recruiting |
| Institut Gustave Roussy | Villejuif, France | Not Yet Recruiting |
| Hospital Clinic Barcelona | Barcelona, Spain | Recruiting |
| Institut Catala d'Oncologia | Barcelona, Spain | Recruiting |
| Hospital General Universitario Gregorio Maranon | Madrid, Spain | Not Yet Recruiting |
| Hospital 12 de Octubre | Madrid, Spain | Recruiting |
| Instituto Valenciano de Oncología | Valencia, Spain | Not Yet Recruiting |
| Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospita | Cambridge, United Kingdom | Not Yet Recruiting |
| University Hospital Southampton NHS Foundation Trust - Southampton General Hospital | Southampton, United Kingdom | Not Yet Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06190899